Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...
Hosted on MSN15d
Here's What to Expect From Moderna's Next Earnings ReportModerna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering messenger RNA (mRNA) therapeutics and vaccines to transform the future of ...
The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018 ...
Moderna is developing more than 40 mRNA-based ... combination of elements to beat onearnings this time around: CRISPR Therapeutics CRSP has an Earnings ESP of +8.09% and a Zacks Rank #3 at present.
Moderna and Merck rapidly expanded clinical studies to additional tumor types and the Phase 3 clinical trial for adjuvant melanoma completed enrollment in 2024. Rare disease therapeutics ...
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...
Moderna provides updates on its business and ... three regulatory filings seeking the FDA’s approval. Intellia Therapeutics announced its strategic priorities and key anticipated milestones ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback